The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis

Time: 10:15 am
day: Day One


  • The story from discovery to clinical development for a moderate to severe
    inflammatory skin indication
  • Inspecting the JAK/STAT pathways critical to Incyte’s JAK inhibitor portfolio
  • Reviewing the commercialization and market strategy of a ‘twice daily’ applied
    topical cream